Skip to main content
. Author manuscript; available in PMC: 2012 Jul 23.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008305. doi: 10.1002/14651858.CD008305.pub2

Appendix 6. Baseline characteristics (part 2).

Characteris-
tic		 Jing A, 2009 Li KL, 2006 Li LH, 2005 Liu L, 2000 Lu GP, 1998 Ma YL, 2002 Qi MY, 2004
Interven-
tion(s) & con-
trol(s)		 I: DMC C: pravastatin I: Xuezhikang
C: simvastatin		 I: Xuezhikang
C1:
simvastatin
C2:
pravastatin		 I: Xuezhikang
C: inositol
nicotinate		 I: Xuezhikang
C: simvastatin		 I: Xuezhikang
C: marine
triglycerids		 I: Xuezhikang
C: simvastatin
Participating
population		 60 80 60 118 28 60 224
Sex [female%
/ male%]		 ./. 31.25%/
68.75%
(25/55)		 46.7%/53.
(28/32)		 43.2%/56.8%
(51/67)		 35.7%/64.3%
(10/18)		 53.3%/46.7%
(32/28)		 ./.
Age [mean
years (SD)]		 ./. ./. ./. ./. ./. ./. ./.
Duration of
disease [mean
years (SD)]		 ./. ./. ./. ./. ./. ./. ./.
Ethnic groups
[%]		 Chinese: 100 Chinese: 100 Chinese: 100 Chinese: 100 Chinese: 100 Chinese: 100 Chinese: 100
Duration of
intervention		 6 weeks 8 weeks 12 weeks 24 weeks 12 weeks 4 weeks 8 weeks
Duration of
follow up		 ./. ./. ./. ./. ./. ./. ./.

Footnotes

C./.: not reported

C: control; I: intervention.